APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human-mouse Chimeric Antibody Therapeutics

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Human-mouse Chimeric Antibody Therapeutics Industry Growth and Trends Forecast to 2032

23 December 2025113 pages

Choose your research edition.

Industry ResearchHuman-mouse Chimeric Antibody Therapeutics Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Human-mouse Chimeric Antibody Therapeutics Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Human-mouse Chimeric Antibody Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human-mouse Chimeric Antibody Therapeutics Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Human-mouse Chimeric Antibody Therapeutics Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

According to APO Research, the global Human-mouse Chimeric Antibody Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Human-mouse Chimeric Antibody Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Human-mouse Chimeric Antibody Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human-mouse Chimeric Antibody Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Human-mouse Chimeric Antibody Therapeutics market include Innovent Bio, Teva, Shanghai Henlius Biopharmaceutical, Sandoz, Sanofi, Johnson & Johnson, Merck KGaA, Roche AG and Eli Lilly & Co, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Human-mouse Chimeric Antibody Therapeutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Human-mouse Chimeric Antibody Therapeutics market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Human-mouse Chimeric Antibody Therapeutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Human-mouse Chimeric Antibody Therapeutics.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Human-mouse Chimeric Antibody Therapeutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Human-mouse Chimeric Antibody Therapeutics Market by Company

Innovent Bio

Teva

Shanghai Henlius Biopharmaceutical

Sandoz

Sanofi

Johnson & Johnson

Merck KGaA

Roche AG

Eli Lilly & Co

Pfizer

Amgen

United Therapeutics

Mitsubishi Tanabe Pharma

Merck & Co

Kyowa Kirin

Celltrion

Human-mouse Chimeric Antibody Therapeutics Segment by Type

Emicizumab

Esatuximab

Rituximab

Cetuximab

Infliximab

Other

Human-mouse Chimeric Antibody Therapeutics Segment by Application

Autoimmune Diseases

Cancers

Transplant Rejection

Human-mouse Chimeric Antibody Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human-mouse Chimeric Antibody Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human-mouse Chimeric Antibody Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human-mouse Chimeric Antibody Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Human-mouse Chimeric Antibody Therapeutics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Human-mouse Chimeric Antibody Therapeutics Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Human-mouse Chimeric Antibody Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Human-mouse Chimeric Antibody Therapeutics Market Share by Region (2021-2026) Table 4. Global Human-mouse Chimeric Antibody Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Human-mouse Chimeric Antibody Therapeutics Market Share by Region (2027-2032) Table 6. Global Human-mouse Chimeric Antibody Therapeutics Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Human-mouse Chimeric Antibody Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Human-mouse Chimeric Antibody Therapeutics Market Size Share by Type (2021-2026) Table 9. Global Human-mouse Chimeric Antibody Therapeutics Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Human-mouse Chimeric Antibody Therapeutics Market Size Share Forecasted by Type (2027-2032) Table 11. North America Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Human-mouse Chimeric Antibody Therapeutics Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Human-mouse Chimeric Antibody Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Human-mouse Chimeric Antibody Therapeutics Market Size Share by Application (2021-2026) Table 24. Global Human-mouse Chimeric Antibody Therapeutics Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Human-mouse Chimeric Antibody Therapeutics Market Size Share Forecasted by Application (2027-2032) Table 26. North America Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Human-mouse Chimeric Antibody Therapeutics Industry Trends Table 37. Human-mouse Chimeric Antibody Therapeutics Industry Drivers Table 38. Human-mouse Chimeric Antibody Therapeutics Industry Opportunities and Challenges Table 39. Human-mouse Chimeric Antibody Therapeutics Industry Restraints Table 40. Global Human-mouse Chimeric Antibody Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Human-mouse Chimeric Antibody Therapeutics Revenue Market Share by Company (2021-2026) Table 42. Global Human-mouse Chimeric Antibody Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Human-mouse Chimeric Antibody Therapeutics Key Company Headquarters & Area Served Table 44. Global Human-mouse Chimeric Antibody Therapeutics Company, Product Type & Application Table 45. Global Human-mouse Chimeric Antibody Therapeutics Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Human-mouse Chimeric Antibody Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Innovent Bio Company Information Table 49. Innovent Bio Business Overview Table 50. Innovent Bio Human-mouse Chimeric Antibody Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Innovent Bio Human-mouse Chimeric Antibody Therapeutics Product Portfolio Table 52. Innovent Bio Recent Development Table 53. Teva Company Information Table 54. Teva Business Overview Table 55. Teva Human-mouse Chimeric Antibody Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Teva Human-mouse Chimeric Antibody Therapeutics Product Portfolio Table 57. Teva Recent Development Table 58. Shanghai Henlius Biopharmaceutical Company Information Table 59. Shanghai Henlius Biopharmaceutical Business Overview Table 60. Shanghai Henlius Biopharmaceutical Human-mouse Chimeric Antibody Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Shanghai Henlius Biopharmaceutical Human-mouse Chimeric Antibody Therapeutics Product Portfolio Table 62. Shanghai Henlius Biopharmaceutical Recent Development Table 63. Sandoz Company Information Table 64. Sandoz Business Overview Table 65. Sandoz Human-mouse Chimeric Antibody Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Sandoz Human-mouse Chimeric Antibody Therapeutics Product Portfolio Table 67. Sandoz Recent Development Table 68. Sanofi Company Information Table 69. Sanofi Business Overview Table 70. Sanofi Human-mouse Chimeric Antibody Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Sanofi Human-mouse Chimeric Antibody Therapeutics Product Portfolio Table 72. Sanofi Recent Development Table 73. Johnson & Johnson Company Information Table 74. Johnson & Johnson Business Overview Table 75. Johnson & Johnson Human-mouse Chimeric Antibody Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Johnson & Johnson Human-mouse Chimeric Antibody Therapeutics Product Portfolio Table 77. Johnson & Johnson Recent Development Table 78. Merck KGaA Company Information Table 79. Merck KGaA Business Overview Table 80. Merck KGaA Human-mouse Chimeric Antibody Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Merck KGaA Human-mouse Chimeric Antibody Therapeutics Product Portfolio Table 82. Merck KGaA Recent Development Table 83. Roche AG Company Information Table 84. Roche AG Business Overview Table 85. Roche AG Human-mouse Chimeric Antibody Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Roche AG Human-mouse Chimeric Antibody Therapeutics Product Portfolio Table 87. Roche AG Recent Development Table 88. Eli Lilly & Co Company Information Table 89. Eli Lilly & Co Business Overview Table 90. Eli Lilly & Co Human-mouse Chimeric Antibody Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Eli Lilly & Co Human-mouse Chimeric Antibody Therapeutics Product Portfolio Table 92. Eli Lilly & Co Recent Development Table 93. Pfizer Company Information Table 94. Pfizer Business Overview Table 95. Pfizer Human-mouse Chimeric Antibody Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Pfizer Human-mouse Chimeric Antibody Therapeutics Product Portfolio Table 97. Pfizer Recent Development Table 98. Amgen Company Information Table 99. Amgen Business Overview Table 100. Amgen Human-mouse Chimeric Antibody Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Amgen Human-mouse Chimeric Antibody Therapeutics Product Portfolio Table 102. Amgen Recent Development Table 103. United Therapeutics Company Information Table 104. United Therapeutics Business Overview Table 105. United Therapeutics Human-mouse Chimeric Antibody Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. United Therapeutics Human-mouse Chimeric Antibody Therapeutics Product Portfolio Table 107. United Therapeutics Recent Development Table 108. Mitsubishi Tanabe Pharma Company Information Table 109. Mitsubishi Tanabe Pharma Business Overview Table 110. Mitsubishi Tanabe Pharma Human-mouse Chimeric Antibody Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Mitsubishi Tanabe Pharma Human-mouse Chimeric Antibody Therapeutics Product Portfolio Table 112. Mitsubishi Tanabe Pharma Recent Development Table 113. Merck & Co Company Information Table 114. Merck & Co Business Overview Table 115. Merck & Co Human-mouse Chimeric Antibody Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Merck & Co Human-mouse Chimeric Antibody Therapeutics Product Portfolio Table 117. Merck & Co Recent Development Table 118. Kyowa Kirin Company Information Table 119. Kyowa Kirin Business Overview Table 120. Kyowa Kirin Human-mouse Chimeric Antibody Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Kyowa Kirin Human-mouse Chimeric Antibody Therapeutics Product Portfolio Table 122. Kyowa Kirin Recent Development Table 123. Celltrion Company Information Table 124. Celltrion Business Overview Table 125. Celltrion Human-mouse Chimeric Antibody Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Celltrion Human-mouse Chimeric Antibody Therapeutics Product Portfolio Table 127. Celltrion Recent Development Table 128. North America Human-mouse Chimeric Antibody Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. North America Human-mouse Chimeric Antibody Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 130. North America Human-mouse Chimeric Antibody Therapeutics Market Share by Country (2021-2026) Table 131. North America Human-mouse Chimeric Antibody Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. North America Human-mouse Chimeric Antibody Therapeutics Market Share Forecast by Country (2027-2032) Table 133. Europe Human-mouse Chimeric Antibody Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. Europe Human-mouse Chimeric Antibody Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 135. Europe Human-mouse Chimeric Antibody Therapeutics Market Share by Country (2021-2026) Table 136. Europe Human-mouse Chimeric Antibody Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. Europe Human-mouse Chimeric Antibody Therapeutics Market Share Forecast by Country (2027-2032) Table 138. Asia-Pacific Human-mouse Chimeric Antibody Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Asia-Pacific Human-mouse Chimeric Antibody Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 140. Asia-Pacific Human-mouse Chimeric Antibody Therapeutics Market Share by Country (2021-2026) Table 141. Asia-Pacific Human-mouse Chimeric Antibody Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Asia-Pacific Human-mouse Chimeric Antibody Therapeutics Market Share Forecast by Country (2027-2032) Table 143. Latin America Human-mouse Chimeric Antibody Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Latin America Human-mouse Chimeric Antibody Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 145. Latin America Human-mouse Chimeric Antibody Therapeutics Market Share by Country (2021-2026) Table 146. Latin America Human-mouse Chimeric Antibody Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Latin America Human-mouse Chimeric Antibody Therapeutics Market Share Forecast by Country (2027-2032) Table 148. Middle East & Africa Human-mouse Chimeric Antibody Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Middle East & Africa Human-mouse Chimeric Antibody Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 150. Middle East & Africa Human-mouse Chimeric Antibody Therapeutics Market Share by Country (2021-2026) Table 151. Middle East & Africa Human-mouse Chimeric Antibody Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Middle East & Africa Human-mouse Chimeric Antibody Therapeutics Market Share Forecast by Country (2027-2032) Table 153. Research Programs/Design for This Report Table 154. Authors List of This Report Table 155. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Human-mouse Chimeric Antibody Therapeutics Product Image Figure 3. Global Human-mouse Chimeric Antibody Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Human-mouse Chimeric Antibody Therapeutics Market Size (2021-2032) & (US$ Million) Figure 5. Global Human-mouse Chimeric Antibody Therapeutics Market Share by Region: 2025 VS 2032 Figure 6. Global Human-mouse Chimeric Antibody Therapeutics Market Share by Region (2021-2032) Figure 7. North America Human-mouse Chimeric Antibody Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Human-mouse Chimeric Antibody Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Human-mouse Chimeric Antibody Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Human-mouse Chimeric Antibody Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Human-mouse Chimeric Antibody Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Emicizumab Image Figure 13. Global Emicizumab Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Esatuximab Image Figure 15. Global Esatuximab Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Rituximab Image Figure 17. Global Rituximab Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Cetuximab Image Figure 19. Global Cetuximab Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Infliximab Image Figure 21. Global Infliximab Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. Other Image Figure 23. Global Other Market Size YoY Growth (2021-2032) & (US$ Million) Figure 24. Global Human-mouse Chimeric Antibody Therapeutics Market Size Overview by Type (2021-2032) & (US$ Million) Figure 25. Global Human-mouse Chimeric Antibody Therapeutics Market Share by Type 2025 VS 2032 Figure 26. North America Human-mouse Chimeric Antibody Therapeutics Market Size Share by Type (2021-2032) Figure 27. Europe Human-mouse Chimeric Antibody Therapeutics Market Size Share by Type (2021-2032) Figure 28. Asia-Pacific Human-mouse Chimeric Antibody Therapeutics Market Size Share by Type (2021-2032) Figure 29. Latin America Human-mouse Chimeric Antibody Therapeutics Market Size Share by Type (2021-2032) Figure 30. Middle East and Africa Human-mouse Chimeric Antibody Therapeutics Market Size Share by Type (2021-2032) Figure 31. Autoimmune Diseases Image Figure 32. Global Autoimmune Diseases Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Cancers Image Figure 34. Global Cancers Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Transplant Rejection Image Figure 36. Global Transplant Rejection Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Global Human-mouse Chimeric Antibody Therapeutics Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Human-mouse Chimeric Antibody Therapeutics Market Share by Application 2025 VS 2032 Figure 39. North America Human-mouse Chimeric Antibody Therapeutics Market Size Share by Application (2021-2032) Figure 40. Europe Human-mouse Chimeric Antibody Therapeutics Market Size Share by Application (2021-2032) Figure 41. Asia-Pacific Human-mouse Chimeric Antibody Therapeutics Market Size Share by Application (2021-2032) Figure 42. Latin America Human-mouse Chimeric Antibody Therapeutics Market Size Share by Application (2021-2032) Figure 43. Middle East and Africa Human-mouse Chimeric Antibody Therapeutics Market Size Share by Application (2021-2032) Figure 44. Global Top 5 and 10 Human-mouse Chimeric Antibody Therapeutics Players Market Share by Revenue in 2025 Figure 45. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 46. North America Human-mouse Chimeric Antibody Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 47. North America Human-mouse Chimeric Antibody Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 48. North America Human-mouse Chimeric Antibody Therapeutics Market Share by Country (2021-2032) Figure 49. Europe Human-mouse Chimeric Antibody Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Human-mouse Chimeric Antibody Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Human-mouse Chimeric Antibody Therapeutics Market Share by Country (2021-2032) Figure 52. Asia-Pacific Human-mouse Chimeric Antibody Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 53. Asia-Pacific Human-mouse Chimeric Antibody Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 54. Asia-Pacific Human-mouse Chimeric Antibody Therapeutics Market Share by Country (2021-2032) Figure 55. Latin America Human-mouse Chimeric Antibody Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Human-mouse Chimeric Antibody Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Human-mouse Chimeric Antibody Therapeutics Market Share by Country (2021-2032) Figure 58. Middle East & Africa Human-mouse Chimeric Antibody Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Middle East & Africa Human-mouse Chimeric Antibody Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 60. Middle East & Africa Human-mouse Chimeric Antibody Therapeutics Market Share by Country (2021-2032) Figure 61. Years Considered Figure 62. Research Process Figure 63. Key Executives Interviewed

Scope & coverage.

Types
  • Emicizumab
  • Esatuximab
  • Rituximab
  • Cetuximab
  • Infliximab
  • Other
Applications
  • Autoimmune Diseases
  • Cancers
  • Transplant Rejection
Companies covered
  • Innovent Bio
  • Teva
  • Shanghai Henlius Biopharmaceutical
  • Sandoz
  • Sanofi
  • Johnson & Johnson
  • Merck KGaA
  • Roche AG
  • Eli Lilly & Co
  • Pfizer
  • Amgen
  • United Therapeutics
  • Mitsubishi Tanabe Pharma
  • Merck & Co
  • Kyowa Kirin
  • Celltrion

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Human-mouse Chimeric Antibody Therapeutics Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Human-mouse Chimeric Antibody Therapeutics Market Size by Region (2021-2032)
  5. 1.4.1 Global Human-mouse Chimeric Antibody Therapeutics Market Size by Region (2021-2026)
  6. 1.4.2 Global Human-mouse Chimeric Antibody Therapeutics Market Size by Region (2027-2032)
  7. 1.5 Key Regions Human-mouse Chimeric Antibody Therapeutics Market Size (2021-2032)
  8. 1.5.1 North America Human-mouse Chimeric Antibody Therapeutics Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Human-mouse Chimeric Antibody Therapeutics Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Human-mouse Chimeric Antibody Therapeutics Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Human-mouse Chimeric Antibody Therapeutics Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Human-mouse Chimeric Antibody Therapeutics Market Size Growth Rate (2021-2032)
2 Human-mouse Chimeric Antibody Therapeutics Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Emicizumab
  3. 2.1.2 Esatuximab
  4. 2.1.3 Rituximab
  5. 2.1.4 Cetuximab
  6. 2.1.5 Infliximab
  7. 2.1.6 Other
  8. 2.2 Global Human-mouse Chimeric Antibody Therapeutics Market Size by Type
  9. 2.2.1 Global Human-mouse Chimeric Antibody Therapeutics Market Size Overview by Type (2021-2032)
  10. 2.2.2 Global Human-mouse Chimeric Antibody Therapeutics Historic Market Size Review by Type (2021-2026)
  11. 2.2.3 Global Human-mouse Chimeric Antibody Therapeutics Market Size Forecasted by Type (2027-2032)
  12. 2.3 Global Human-mouse Chimeric Antibody Therapeutics Market Size by Regions
  13. 2.3.1 North America Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Type (2021-2026)
  14. 2.3.2 Europe Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Type (2021-2026)
  15. 2.3.3 Asia-Pacific Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Type (2021-2026)
  16. 2.3.4 South America Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Type (2021-2026)
  17. 2.3.5 Middle East and Africa Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Type (2021-2026)
3 Human-mouse Chimeric Antibody Therapeutics Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Autoimmune Diseases
  3. 3.1.2 Cancers
  4. 3.1.3 Transplant Rejection
  5. 3.2 Global Human-mouse Chimeric Antibody Therapeutics Market Size by Application
  6. 3.2.1 Global Human-mouse Chimeric Antibody Therapeutics Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Human-mouse Chimeric Antibody Therapeutics Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Human-mouse Chimeric Antibody Therapeutics Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Human-mouse Chimeric Antibody Therapeutics Market Size by Regions
  10. 3.3.1 North America Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Human-mouse Chimeric Antibody Therapeutics Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Human-mouse Chimeric Antibody Therapeutics Industry Trends
  2. 4.2 Human-mouse Chimeric Antibody Therapeutics Industry Drivers
  3. 4.3 Human-mouse Chimeric Antibody Therapeutics Industry Opportunities and Challenges
  4. 4.4 Human-mouse Chimeric Antibody Therapeutics Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Human-mouse Chimeric Antibody Therapeutics Revenue (2021-2026)
  2. 5.2 Global Human-mouse Chimeric Antibody Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Human-mouse Chimeric Antibody Therapeutics Key Company Headquarters & Area Served
  4. 5.4 Global Human-mouse Chimeric Antibody Therapeutics Company, Product Type & Application
  5. 5.5 Global Human-mouse Chimeric Antibody Therapeutics Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Human-mouse Chimeric Antibody Therapeutics Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Human-mouse Chimeric Antibody Therapeutics Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Human-mouse Chimeric Antibody Therapeutics Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Innovent Bio
  2. 6.1.1 Innovent Bio Company Information
  3. 6.1.2 Innovent Bio Business Overview
  4. 6.1.3 Innovent Bio Human-mouse Chimeric Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Innovent Bio Human-mouse Chimeric Antibody Therapeutics Product Portfolio
  6. 6.1.5 Innovent Bio Recent Developments
  7. 6.2 Teva
  8. 6.2.1 Teva Company Information
  9. 6.2.2 Teva Business Overview
  10. 6.2.3 Teva Human-mouse Chimeric Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Teva Human-mouse Chimeric Antibody Therapeutics Product Portfolio
  12. 6.2.5 Teva Recent Developments
  13. 6.3 Shanghai Henlius Biopharmaceutical
  14. 6.3.1 Shanghai Henlius Biopharmaceutical Company Information
  15. 6.3.2 Shanghai Henlius Biopharmaceutical Business Overview
  16. 6.3.3 Shanghai Henlius Biopharmaceutical Human-mouse Chimeric Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Shanghai Henlius Biopharmaceutical Human-mouse Chimeric Antibody Therapeutics Product Portfolio
  18. 6.3.5 Shanghai Henlius Biopharmaceutical Recent Developments
  19. 6.4 Sandoz
  20. 6.4.1 Sandoz Company Information
  21. 6.4.2 Sandoz Business Overview
  22. 6.4.3 Sandoz Human-mouse Chimeric Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Sandoz Human-mouse Chimeric Antibody Therapeutics Product Portfolio
  24. 6.4.5 Sandoz Recent Developments
  25. 6.5 Sanofi
  26. 6.5.1 Sanofi Company Information
  27. 6.5.2 Sanofi Business Overview
  28. 6.5.3 Sanofi Human-mouse Chimeric Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Sanofi Human-mouse Chimeric Antibody Therapeutics Product Portfolio
  30. 6.5.5 Sanofi Recent Developments
  31. 6.6 Johnson & Johnson
  32. 6.6.1 Johnson & Johnson Company Information
  33. 6.6.2 Johnson & Johnson Business Overview
  34. 6.6.3 Johnson & Johnson Human-mouse Chimeric Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Johnson & Johnson Human-mouse Chimeric Antibody Therapeutics Product Portfolio
  36. 6.6.5 Johnson & Johnson Recent Developments
  37. 6.7 Merck KGaA
  38. 6.7.1 Merck KGaA Company Information
  39. 6.7.2 Merck KGaA Business Overview
  40. 6.7.3 Merck KGaA Human-mouse Chimeric Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Merck KGaA Human-mouse Chimeric Antibody Therapeutics Product Portfolio
  42. 6.7.5 Merck KGaA Recent Developments
  43. 6.8 Roche AG
  44. 6.8.1 Roche AG Company Information
  45. 6.8.2 Roche AG Business Overview
  46. 6.8.3 Roche AG Human-mouse Chimeric Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Roche AG Human-mouse Chimeric Antibody Therapeutics Product Portfolio
  48. 6.8.5 Roche AG Recent Developments
  49. 6.9 Eli Lilly & Co
  50. 6.9.1 Eli Lilly & Co Company Information
  51. 6.9.2 Eli Lilly & Co Business Overview
  52. 6.9.3 Eli Lilly & Co Human-mouse Chimeric Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Eli Lilly & Co Human-mouse Chimeric Antibody Therapeutics Product Portfolio
  54. 6.9.5 Eli Lilly & Co Recent Developments
  55. 6.10 Pfizer
  56. 6.10.1 Pfizer Company Information
  57. 6.10.2 Pfizer Business Overview
  58. 6.10.3 Pfizer Human-mouse Chimeric Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Pfizer Human-mouse Chimeric Antibody Therapeutics Product Portfolio
  60. 6.10.5 Pfizer Recent Developments
  61. 6.11 Amgen
  62. 6.11.1 Amgen Company Information
  63. 6.11.2 Amgen Business Overview
  64. 6.11.3 Amgen Human-mouse Chimeric Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Amgen Human-mouse Chimeric Antibody Therapeutics Product Portfolio
  66. 6.11.5 Amgen Recent Developments
  67. 6.12 United Therapeutics
  68. 6.12.1 United Therapeutics Company Information
  69. 6.12.2 United Therapeutics Business Overview
  70. 6.12.3 United Therapeutics Human-mouse Chimeric Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 United Therapeutics Human-mouse Chimeric Antibody Therapeutics Product Portfolio
  72. 6.12.5 United Therapeutics Recent Developments
  73. 6.13 Mitsubishi Tanabe Pharma
  74. 6.13.1 Mitsubishi Tanabe Pharma Company Information
  75. 6.13.2 Mitsubishi Tanabe Pharma Business Overview
  76. 6.13.3 Mitsubishi Tanabe Pharma Human-mouse Chimeric Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Mitsubishi Tanabe Pharma Human-mouse Chimeric Antibody Therapeutics Product Portfolio
  78. 6.13.5 Mitsubishi Tanabe Pharma Recent Developments
  79. 6.14 Merck & Co
  80. 6.14.1 Merck & Co Company Information
  81. 6.14.2 Merck & Co Business Overview
  82. 6.14.3 Merck & Co Human-mouse Chimeric Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Merck & Co Human-mouse Chimeric Antibody Therapeutics Product Portfolio
  84. 6.14.5 Merck & Co Recent Developments
  85. 6.15 Kyowa Kirin
  86. 6.15.1 Kyowa Kirin Company Information
  87. 6.15.2 Kyowa Kirin Business Overview
  88. 6.15.3 Kyowa Kirin Human-mouse Chimeric Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Kyowa Kirin Human-mouse Chimeric Antibody Therapeutics Product Portfolio
  90. 6.15.5 Kyowa Kirin Recent Developments
  91. 6.16 Celltrion
  92. 6.16.1 Celltrion Company Information
  93. 6.16.2 Celltrion Business Overview
  94. 6.16.3 Celltrion Human-mouse Chimeric Antibody Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Celltrion Human-mouse Chimeric Antibody Therapeutics Product Portfolio
  96. 6.16.5 Celltrion Recent Developments
7 North America
  1. 7.1 North America Human-mouse Chimeric Antibody Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Human-mouse Chimeric Antibody Therapeutics Market Size by Country (2021-2026)
  3. 7.3 North America Human-mouse Chimeric Antibody Therapeutics Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Human-mouse Chimeric Antibody Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Human-mouse Chimeric Antibody Therapeutics Market Size by Country (2021-2026)
  3. 8.3 Europe Human-mouse Chimeric Antibody Therapeutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Human-mouse Chimeric Antibody Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Human-mouse Chimeric Antibody Therapeutics Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Human-mouse Chimeric Antibody Therapeutics Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Human-mouse Chimeric Antibody Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Human-mouse Chimeric Antibody Therapeutics Market Size by Country (2021-2026)
  3. 10.3 South America Human-mouse Chimeric Antibody Therapeutics Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Human-mouse Chimeric Antibody Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Human-mouse Chimeric Antibody Therapeutics Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Human-mouse Chimeric Antibody Therapeutics Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst